Combination of two hypoglycemic drugs for type 2 diabetes mellitus
- Autores: Morgunova T.B.1, Fadeyev V.V1
-
Afiliações:
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Edição: Volume 27, Nº 12 (2020)
- Páginas: 33-37
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312917
- DOI: https://doi.org/10.18565/pharmateca.2020.12.33-37
- ID: 312917
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Type 2 diabetes mellitus is a chronic progressive disease, which is based on a combination of several mechanisms leading to the development and progression of hyperglycemia. Over the past decades, new classes of hypoglycemic drugs have been used in clinical practice, affecting different links in the pathogenesis of the disease. The question of the possible earlier prescription of a combination of hypoglycemic drugs with different mechanisms of action is being discussed more and more often. This article discusses the advantages and disadvantages of different options for combined glucose-lowering therapy in patients with type 2 diabetes.
Texto integral
Sobre autores
Tatyana Morgunova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: tanmorgun@mail.ru
Cand. Sci. (Med.) 8-2, Trubetskaya str., Moscow 119991, Russian Federation
V. Fadeyev
I.M. Sechenov First Moscow State Medical University (Sechenov University)Moscow, Russia
Bibliografia
- IDF. Diabetes Atlas 8th ed. 2017. URL: https://diabetesatlas.org/resources/20l7-atlas.html.
- Dedov I., Shestakova M, Benedetti M.M., et al. Prevalence of Type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabet Res Clin Pract. 2016;115:90-5. doi: 10.1016/j.diabres.2016.02.010.
- Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск. М., 2019. doi: 10.14341/DM20151S1-112.
- American Diabetes Association. Diabet Care. 2020;43(Suppl. 1):S98-110. Doi: https://doi. org/10.2337/dc20-S009.
- Khunti K., Ceriello A., Cos X., De Block C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis. Diabet Res Clin Pract. 2018;137:137-48. doi: 10.1016/j.diabres.2017.12.004.
- Paul S.K., Klein K., Thorsted B.L., et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc. Diabetol. 2015;14:100. doi: 10.1186/s12933-015-0260-x.
- Gastaldelli A., Ferrannini E., Miyazaki Y., et al. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetol. 2004;47(1):31-9. doi: 10.1007/s00125-003-1263-9.
- Raz I., Mosenzon O. Early insulinization to prevent diabetes progression. Diabet Care. 2013;36(Suppl. 2):S190-97. doi: 10.2337/dcS13-2014.
- Matthews D.R., Paldânius P.M., Proot P., et al.; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519-29. doi: 10.1016/S0140-6736(19)32131-2.
- Шестакова М.В., Качко В.А. ENTIRE: исследование реальной клинической практики применения алоглиптина в терапии пациентов с сахарным диабетом 2 типа в РФ. РМЖ. 2019;8(!):3-10.
Arquivos suplementares
